comparemela.com

Page 4 - Baxalta Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

USPTO Says Wands Is Still The Test Post-Amgen - Trademark

The United States Patent and Trademark Office issued a notice in the Federal Register on January 10, 2024, providing guidelines to assist USPTO personnel.

USPTO Provides Guidance on Standards for Enablement Requirement | McDonnell Boehnen Hulbert & Berghoff LLP

Amgen v Sanofi: Seven Months In, Has Anything About Patent Enablement Changed?

Last term, the U.S. Supreme Court did something strange: the Court unanimously affirmed a circuit decision, which had unanimously affirmed a trial court decision. Little about the law seemed ripe for dispute or change, nevertheless, in Amgen v. Sanofi the Supreme Court spoke.

In the Aftermath of Amgen v Sanofi, Federal Circuit Finds Functional Antibody Claims Invalid for Lack of Enablement | Akin Gump Strauss Hauer & Feld LLP

Applying the Supreme Court’s Amgen v. Sanofi decision for the first time, the Federal Circuit recently affirmed a district court decision finding claims to antibodies characterized by.

Five Golden CAFC Patent Cases of 2023

As 2023 draws to a close, here’s a gift of five golden Federal Circuit patent cases!  These decisions issued by the U.S. Court of Appeals for the Federal Circuit (CAFC) significantly impact patent practitioners in several areas, including patent prosecution, litigation, and inter partes reviews (IPRs).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.